Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
9Customers
3Debt Items
1Related Chains
Source-Backed Evidence Depth
NovaBay Pharmaceuticals Inc (NBY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
3Distinct source URLs
10High confidence
0.784Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
NovaBay Pharmaceuticals Inc Suppliers
Ticker
Name
Confidence
Evidence
R01
R01
90%
Consulting agreement R01 has provided certain consulting services to the Company through one of its employees.
FRAMEWORK
FRAMEWORK
85%
On October 16, 2025, the Company issued and sold pre-funded warrants (the "October 2025 Pre-Funded Warrants") to R01 and Framework in two transactions for aggregate net proceeds of approximately $ 5.…
FIREBLOCKS
FIREBLOCKS
80%
the substantial majority of the Company's SKY tokens are held in self-custody using the MPC key management platform provided by Fireblocks.
KRAKEN
KRAKEN
80%
The Company maintains the ability to custody digital assets with Kraken and may reallocate assets among service providers from time to time.
NovaBay Pharmaceuticals Inc Customers
Ticker
Name
Confidence
Evidence
PHASEONE
PHASEONE
92%
the Company sold the Company’s existing PhaseOne finished goods inventory from an outstanding purchase order to PhaseOne for an aggregate payment of $ 126,000
PRN-PHYSICIAN-RECOMMENDED-NUTRICEUTICALS-LLC
PRN-PHYSICIAN-RECOMMENDED-NUTRICEUTICALS-LLC
92%
On January 17, 2025, the Company completed the sale of its eyecare products sold under the Avenova brand and related assets (the “Avenova Assets”) to PRN Physician Recommended Nutriceuticals, LLC, a …
tomers. The Company’s estimated allowance for product returns requires a high degree of judgment and is subject to change based on various quantitative and qualitative factors. Accordingly, extensive…
Reciprocal relationship from SDEV graph: Reciprocal relationship from NBY graph: Reciprocal relationship from SDEV graph: Reciprocal relationship from NBY graph: tomers. The Company’s estimated allow…
CHONGQING-PIONEER-PHARMA-HOLDINGS-LIMITED
CHONGQING-PIONEER-PHARMA-HOLDINGS-LIMITED
62%
Item 8 of this annual report. PhaseOne Divestiture On January 8, 2025, we completed the sale of our wound care product trademarks, including NeutroPhase, PhaseOne and OmniPhase, and related inventory…
EMERYVILLE-LLC
EMERYVILLE-LLC
62%
onfidentiality/invention rights agreements with employees, confidentiality agreements with manufacturers, proprietary expertise and product formulations, continuing innovation efforts and techniques,…
PAYWARD-FINANCIAL-INC
PAYWARD-FINANCIAL-INC
62%
ain governance of the Sky Protocol. Staking rewards are determined by protocol governance parameters, participation levels, and other factors, and are subject to variability over time. SKY tokens are…
PHASE-ONE-HEALTH-LLC
PHASE-ONE-HEALTH-LLC
62%
Item 8 of this annual report. PhaseOne Divestiture On January 8, 2025, we completed the sale of our wound care product trademarks, including NeutroPhase, PhaseOne and OmniPhase, and related inventory…
SABBY-VOLATILITY-WARRANT-MASTER-FUND-LTD
SABBY-VOLATILITY-WARRANT-MASTER-FUND-LTD
62%
Stock into common stock triggered the anti-dilution adjustment provisions. As a result, (i) the exercise price of the October 2025 Pre-Funded Warrants was reduced to $ 0.002385 per share, and (ii) th…
NovaBay Pharmaceuticals Inc Debt Obligations
Instrument
Description
Confidence
Evidence
NBY-DEBT
Debt stack $776,000
90%
Market cache reports total debt of $776,000.
NBY-DEBT-11186
Warrants outstanding: 363523
90%
xbrl warrant detail from xbrl 2026-03-31.
NBY-DEBT-11187
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
NovaBay Pharmaceuticals Inc Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc Ownership
Holder
Name
Confidence
Evidence
NBY-OWNER-GOLDMAN-SACHS-GROUP-INC
GOLDMAN SACHS GROUP INC
90%
13F overlay lists GOLDMAN SACHS GROUP INC as top holder; 2 tracked holders.
